We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Rofecoxib and the Risk of Adverse Upper Gastrointestinal Effects

James Freston, MD
JAMA. 2000;283(15):1960-1961. doi:10.1001/jama.283.15.1957.
Text Size: A A A
Published online


To the Editor: In the study by Dr Langman and colleagues,1 data from several studies were pooled prospectively, and the results were interpreted to indicate that "rofecoxib was associated with a significantly lower incidence of PUBs [upper gastrointestinal tract perforations, symptomatic gastroduodenal ulcers, and upper gastrointestinal tract bleeding] than treatment with NSAIDs [nonsteroidal anti-inflammatory drugs]." The consistent use of this terminology throughout the manuscript implies that rofecoxib is not an NSAID (which it is) and that all of the drugs to which it was compared belong to a class that is dissimilar to rofecoxib. The latter conclusion cannot be supported from the data presented. The authors did certain analyses and concluded that "a common RR [relative risk for the comparators] was appropriate." The nonsignificant test for treatment by protocol interaction cannot be taken as proof of homogeneity because this test has very low power in the presence of so few events. Furthermore, with no PUBs associated with 1 of the comparators, nabumetone, there is nothing to suggest that the PUB rate of nabumetone is not as good as or better than that of rofecoxib.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.